The efficacy of immune checkpoint inhibitors in thoracic malignancies

• Published in: European respiratory review Vol. 30; no. 162; p. 200387
• Main Authors: Remon, Jordi, Facchinetti, Francesco, Besse, Benjamin
• Format: Journal Article
• Language: English
• Published: England European Respiratory Society 31-12-2021
• Subjects: Carcinoma, Non-Small-Cell Lung - drug therapy; Humans; Immune Checkpoint Inhibitors; Immunotherapy - adverse effects; Lung Neoplasms - drug therapy; Series; Thoracic Neoplasms - drug therapy
• ISSN: 0905-9180; 1600-0617; 1600-0617
• DOI: 10.1183/16000617.0387-2020

The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small cell lung cancer (NSCLC), ICIs have shifted treatment paradigm and improved overall survival reaching almost one-third of patients alive at 5 years. ICIs therapies have also modified the therapeutic strategy in first-line setting in metastatic small-cell lung cancer (SCLC) patients as well as in malignant pleural mesothelioma (MPM) improving the overall survival compared with standard treatment. This phenomenon is of huge relevance as both SCLC and MPM were considered orphan diseases without any significant improvement in the therapeutic strategy in the first-line setting during the last 15 years. In this review, we aim to review the efficacy of ICI in thoracic malignancies either in monotherapy or in combination, according to predictive biomarkers, and to the US Food and Drug Administration and the European Medicines Agency approvals of treatment strategies. We address the efficacy of these agents, especially in NSCLC according to PD-L1 expression and histologic subtype.